Extended Data Fig. 7: CD8 T cells and Batf3 are critical for therapeutic efficacy. | Nature Cancer

Extended Data Fig. 7: CD8 T cells and Batf3 are critical for therapeutic efficacy.

From: Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity

Extended Data Fig. 7

a, Mice treated as in Fig. 4b that rejected their primary tumor (Naïve n=12 mice/group, Cured (LNP-Rep(IL-12-alb)) n=14 mice/group, Cured (LNP-Rep(IL-12-alb-lum)) n=14 mice/group) were administered antibodies against CD8a beginning one day prior to rechallenge with 0.1x106 B16F10 cells. Then antibody against CD8a was administered every 3 days and followed for survival mice were observed. b, B16F10 tumor bearing mice in absence of Batf3 decreases responses to treatment of LNP-Rep(IL-12-alb). Shown are tumor areas over time after intratumoral injection of LNP-Rep encoding IL-12-alb into B16F10 tumors (mean + s.e.m.) in C57BL/6J or Batf3-/- mice (B6-Untreated n=5 mice/group, B6-LNP-Rep(IL-12-alb) n=7 mice/group, Baft3-/–Untreated n=5 mice/group, Baft3-/–LNP-Rep(IL-12-alb) n=6 mice/group). Throughout, P values were determined by one-sided Log-Rank (Mantel-Cox) test (a), or by one-sided Tukey’s multiple comparison test (b) using PRISM Software and exact P values were indicated.

Source data

Back to article page